Literature DB >> 21663986

Cardiac remodeling induced by 13-cis retinoic acid treatment in acne patients.

Eline A Soriano1, Paula S Azevedo, Hélio A Miot, Marcos F Minicucci, Mariele C Pansani, Luiz S Matsubara, Katashi Okoshi, Leonardo A M Zornoff, Beatriz B Matsubara, Sergio A R Paiva.   

Abstract

BACKGROUND: Currently, 13-cis-retinoic acid (13-cis-RA) is the most effective therapy for acne. Isotretinoin, a first-generation synthetic 13-cis-RA compound, is associated with numerous adverse effects. To investigate the cardiac effects of 13-cis-RA, acne patients receiving 13-cis-RA were studied.
METHODS: Twenty male patients with acne were enrolled in the study. Patients were treated with a dose of 0.5 mg/kg/d of isotretinoin. All participants were assessed prior to treatment and after 10 weeks of therapy with Doppler-echocardiogram.
RESULTS: Patients showed reductions in right atrium vertical diameter, left atrium longitudinal diameter, left atrium volume and left ventricular diastolic diameter over the course of treatment. Significant increases in interventricular septum diastolic thickness, posterior wall diastolic thickness, relative wall relative thickness and left ventricle (LV) mass were observed. The LV mass index showed an increase in ventricular mass and a decrease in the cavity size. Examining LV systolic function, a decrease was observed for the cardiac index.
CONCLUSION: In this study, 10 weeks of 13-cis-RA therapy at a dose of 0.5 mg/kg/d was found to promote concentric-type heart remodeling due to the occurrence of two associated events: heart hypertrophy and hypovolemia.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21663986     DOI: 10.1016/j.ijcard.2011.05.048

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  1 in total

1.  An unknown side effect of isotretinoin: pericardial effusion with atrial tachycardia.

Authors:  Ekrem Güler; Gamze Babur Güler; Cahit Yavuz; Filiz Kızılırmak
Journal:  Anatol J Cardiol       Date:  2015-01-21       Impact factor: 1.596

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.